Intermediary

Quoin Pharmaceuticals Extends Exclusive Distribution Agreement with ER-Kim for its Lead Asset, QRX003, for Netherton Syndrome

Retrieved on: 
Tuesday, March 1, 2022
GLOBE, Partnership, Risk, Growth, NASDAQ, Asthma, Dehydration, Company, Dermatitis, Private Securities Litigation Reform Act, Mutation, Lists of diseases, Netherton, Peeling skin syndrome, Allergy, Intermediary, Biotechnology, CEE, Forward-looking statement, Patient, Netherton syndrome, Epidermolysis bullosa, Infection, SEC, SPINK5, Pharmaceutical industry, Mediterranean Sea, Ichthyosis

Under the terms of the revenue sharing agreement, which was initially announced earlier in February 2022, ER-Kim gains exclusive rights to commercialize QRX003 in six additional countries.

Key Points: 
  • Under the terms of the revenue sharing agreement, which was initially announced earlier in February 2022, ER-Kim gains exclusive rights to commercialize QRX003 in six additional countries.
  • Quoin will be the exclusive supplier of QRX003 to ER-Kim.
  • Quoin now has 60 countries under partnership distribution agreements for QRX003, which has the potential to become the first approved treatment for Netherton Syndrome.
  • Currently, there is no cure for Netherton Syndrome, nor are there any approved therapeutic treatments.

Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with Neopharm for its Lead Asset, QRX003, for Netherton Syndrome

Retrieved on: 
Thursday, February 17, 2022
NASDAQ, Asthma, Patient, Intermediary, Netherton syndrome, Allergy, Health, Company, SPINK5, SEC, Forward-looking statement, Peeling skin syndrome, Infection, Private Securities Litigation Reform Act, Lists of diseases, Dehydration, Mutation, Partnership, Risk, Dermatitis, Growth, GLOBE, Epidermolysis bullosa, Pharmaceutical industry, Ichthyosis

Under the terms of the revenue sharing agreement, Neopharm gains exclusive rights to commercialize QRX003 in Israel.

Key Points: 
  • Under the terms of the revenue sharing agreement, Neopharm gains exclusive rights to commercialize QRX003 in Israel.
  • Quoin will be the exclusive supplier of QRX003 to Neopharm.
  • Dr. Michael Myers, Chief Executive Officer of Quoin, commented, This is Quoins sixth distribution agreement in the last four months for QRX003 and were excited to add Neopharm, who is a leading distributor in Israel.
  • Neopharm Medical Supplies was established in the early 1980s and is the exclusive Israeli distributor of leading medical and pharma manufacturers.

Red Canary Launches Partner Program to Meet Growing Demand for Security Beyond the Endpoint

Retrieved on: 
Tuesday, February 15, 2022
Brown, Ecosystem, Managed services, CEO, CRA International, Risk, CRA, Intermediary, Antigen, Triage, Member of the Scottish Parliament, VP, SOC, Computer security, Service provider, Geography, Insurance, PT, Associate, Red, Partnership, MDR, Brown & Brown, Industry, Program, Channel, Software as a service, Organization, Jamf, Cochineal, Risk management, Red Canary Song

In addition to over 30 existing partners, new partners include Charles River Associates, Antigen Security, Brown & Brown Insurance and Jamf.

Key Points: 
  • In addition to over 30 existing partners, new partners include Charles River Associates, Antigen Security, Brown & Brown Insurance and Jamf.
  • "Red Canary Partner Connect reflects the dynamic and diverse nature of the cybersecurity value-chain, providing a common foundation for all partners to leverage Red Canary while still allowing the flexibility to fit the needs of their business."
  • Unlike other partner programs that do a disservice to their partners by signing up dozens in a particular geography, Red Canary Partner Connect limits partner onboarding and provides specified account managers to each partner.
  • Red Canary will be hosting its first quarterly Partner Update Call on Friday, February 18 at 10 a.m. PT / 1 p.m.

Markets on Main, Inc. Enters Master Distribution Agreement and Marketing Management Agreement

Retrieved on: 
Thursday, February 10, 2022
Woman, GLOBE, Industry, NBC, Intellectual property, Standby Equity Distribution Agreement, Clothing, Elasticity, Acquisition, Distribution, OTC Markets Group, Company, Main, Sale, Effective date, Safety, Intermediary, Marketing, Local marketing agreement, MOM, Attica Market and Main Historic District, SSA Global Technologies, NUE, LaTeX, Judgement, LLC, Cardboard, Online shopping, Velcro, CBD

ST. PETERSBURG, Fla., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Global Technologies, Ltd (OTC Pink: GTLL) (the “Company”), the parent corporation of multiple subsidiaries, that have operations engaged in the online sales of CBD and hemp-related products, the acquisition of intellectual property in the safety and security space, and as a portal for entrepreneurs to provide immediate access to live shopping, e-commerce, distribution and logistics, is pleased to announce that its wholly owned subsidiary, Markets on Main, Inc. (“MOM”) has entered into a Master distribution Agreement and Marketing Management Agreement.On January 19, 2022, MOM entered into an Exclusive Distribution Agreement (the “Distribution Agreement”) with Amfluent, LLC (“Amfluent”). Under the terms of the Distribution Agreement, MOM will become an exclusive distributor for the promotion and sale of products carried by Amfluent. As the exclusive distributor, MOM was awarded the exclusive territory of e-commerce, live shopping and digital sales. The Distribution Agreement has a term of one year from the Effective Date unless both parties agree to renew the Distribution Agreement for an additional term.

Key Points: 
  • On January 19, 2022, MOM entered into an Exclusive Distribution Agreement (the Distribution Agreement) with Amfluent, LLC (Amfluent).
  • The Distribution Agreement has a term of one year from the Effective Date unless both parties agree to renew the Distribution Agreement for an additional term.
  • On January 30, 2022, MOM entered into a Marketing Management Agreement (the Marketing Agreement) with Chin Industries, Inc.
  • Under the terms of the Marketing Agreement, Chin Industries will act as a consultant to manage the day-to-day operations of MOMs ecommerce websites.

Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with ER-Kim for its Lead Asset, QRX003, for Netherton Syndrome

Retrieved on: 
Thursday, February 10, 2022
NASDAQ, Private Securities Litigation Reform Act, Mutation, GLOBE, Forward-looking statement, Growth, CEE, Allergy, Netherton syndrome, Lists of diseases, Company, Infection, Asthma, Dermatitis, Patient, Intermediary, SEC, Epidermolysis bullosa, Biotechnology, Peeling skin syndrome, CIS, SPINK5, Partnership, Dehydration, Risk, Pharmaceutical industry, Ichthyosis, Mediterranean Sea

ASHBURN, Va., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that its wholly-owned subsidiary, Quoin Pharmaceuticals, Inc., has entered into an exclusive Distribution Agreement with ER-Kim, a partner for biotech companies in Central and Eastern Europe (“CCE”), for QRX003, the Company’s investigational treatment for Netherton Syndrome, a rare and devastating genetic disease for which there is currently no available treatment or cure.

Key Points: 
  • Dr. Michael Myers, Chief Executive Officer of Quoin, commented, This is Quoins fifth distribution agreement for QRX003 since we went public four months ago.
  • The agreement with ER-Kim covers a number of important countries for rare and orphan diseases in Central and Eastern Europe.
  • Currently, there is no cure for Netherton Syndrome, nor are there any approved therapeutic treatments.
  • Quoin Pharmaceuticals Ltd. is an emerging specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases.

Nouveau Monde Announces Filing of a Prospectus Supplement for At-The-Market Offering

Retrieved on: 
Friday, January 21, 2022
Mining, Minerals, Natural Resources, Forward-looking statement, ESG, Indian stock exchange, SEDAR, News, Intention, SEC, NMG, Standby Equity Distribution Agreement, Registration statement, COVID-19, NYSE, Roth Capital Partners, Mining, New, Théâtre du Nouveau Monde, Constitution (Amendment No. 1) Act 1925, Risk factor, U.S. Securities and Exchange Commission, Industry, Intermediary, ATM, Agent, Company, NOU, Food and Drug Administration Amendments Act of 2007, United, TSX Venture Exchange, Sale, Canaccord Genuity, Register, Bank, Matawinie Regional County Municipality

Nouveau Monde Graphite Inc. (Nouveau Monde or the Company) ( TSXV: NOU ; NYSE: NMG ; Frankfurt: NM9A ) is pleased to announce that it has filed a prospectus supplement establishing a new at-the-market equity offering (the ATM Offering).

Key Points: 
  • Nouveau Monde Graphite Inc. (Nouveau Monde or the Company) ( TSXV: NOU ; NYSE: NMG ; Frankfurt: NM9A ) is pleased to announce that it has filed a prospectus supplement establishing a new at-the-market equity offering (the ATM Offering).
  • The Company is not obligated to make any sales of Common Shares under the ATM Offering.
  • A prospectus supplement (the "Prospectus Supplement") to the Company's short form base shelf prospectus dated May 19, 2021, as amended by the Amendment No.
  • The Prospectus Supplement, the Base Shelf Prospectus and the Registration Statement contain important detailed information about the Company and the ATM Offering.

Mercer Appoints Holly Verdeyen as US Defined Contribution Leader

Retrieved on: 
Monday, January 10, 2022
Consulting, Professional Services, Human Resources, Finance, Business development, Intermediary, St. Norbert College, LinkedIn, Retirement plans in the United States, Retirement, MBA, NYSE, MMC, Growth, Russell Investments, US Institute for Environmental Conflict Resolution, Environment, Russell, Marsh McLennan, Risk, UBS, Twitter, BlackRock, DC, Organization, CIO, Management, Risk management, Northwestern University

Mercer, a global leader in redefining the world of work, reshaping retirement and investment outcomes, and unlocking real health and well-being, (NYSE: MMC), has named Holly Verdeyen as the US Defined Contribution (DC) Leader.

Key Points: 
  • Mercer, a global leader in redefining the world of work, reshaping retirement and investment outcomes, and unlocking real health and well-being, (NYSE: MMC), has named Holly Verdeyen as the US Defined Contribution (DC) Leader.
  • Based in Chicago, Hollys responsibilities include managing the strategy, development, and growth of Mercers defined contribution and financial wellness business within the US.
  • We are thrilled to welcome Holly to Mercers US Wealth Leadership Team and to lead Mercers Defined Contribution and financial wellness business, said Mahoney.
  • The Defined Contribution space is in a period of exciting but rapid change, with new challenges and opportunities prompting plan sponsors to re-evaluate their governance models.

Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with Orpharm LLC for its Lead Asset, QRX003, for Netherton Syndrome

Retrieved on: 
Wednesday, December 15, 2021
CEE, Forward-looking statement, Dehydration, CIS, Epidermolysis bullosa, Company, Lists of diseases, Dermatitis, Growth, Private Securities Litigation Reform Act, Netherton syndrome, WODA, Allergy, NASDAQ, Dermatology, Degenerative disease, SEC, Intermediary, CEO, Patient, Therapy, Evidence-based medicine, SPINK5, Mutation, Risk, GLOBE, Peeling skin syndrome, Infection, Partnership, Asthma, Compliance, Pharmaceutical industry, Netherton, Ichthyosis

Under the terms of the agreement, Orpharm gains exclusive rights to commercialize QRX003 in Russia and CIS, and Quoin is obligated to supply the product to Orpharm, upon the receipt of regulatory approval.

Key Points: 
  • Under the terms of the agreement, Orpharm gains exclusive rights to commercialize QRX003 in Russia and CIS, and Quoin is obligated to supply the product to Orpharm, upon the receipt of regulatory approval.
  • QRX003 will be a much needed solution to patients suffering from Netherton syndrome in our region.
  • We are committed to supporting Quoin and leveraging our relationships with dermatologists and the broader rare disease community, states Pavel Shestiperov, M.D., CEO of Orpharm.
  • Quoin Pharmaceuticals Ltd. is an emerging specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases.

GoldMining Inc. Announces At-the-Market Equity Program

Retrieved on: 
Friday, December 10, 2021
U.S. Securities and Exchange Commission, Standby Equity Distribution Agreement, Time, Company, LLC, Form, COVID-19, Wainwright Securities Inc. v. Wall Street Transcript Corp., Intermediary, Forward-looking statement, Telephone, NYSE American, Terminology, Sale, Gold, Roth Capital Partners, International Data Group, Toronto Stock Exchange, SEDAR, Natural borrowing limit, Fear, uncertainty, and doubt, EDGAR, News, Agent, GOLD, Industry, Government, National instrument, Acquisition, ATM, NYSE, Program, TSX, Distribution, Goldmining project at Mount Ida region, Cryptocurrency

The Offered Shares sold under the ATM Program, if any, will be sold at the prevailing market price at the time of sale.

Key Points: 
  • The Offered Shares sold under the ATM Program, if any, will be sold at the prevailing market price at the time of sale.
  • GoldMining Inc. is a public mineral exploration company focused on the acquisition and development of gold assets in the Americas.
  • Through its disciplined acquisition strategy, GoldMining now controls a diversified portfolio of resource-stage gold and gold-copper projects in Canada, U.S.A., Brazil, Colombia, and Peru.
  • Forward-looking statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about the business and the markets in which GoldMining operates.

Lumi Appointed as Exclusive Agent for Proxymity in Belgium

Retrieved on: 
Tuesday, December 7, 2021
Computershare, Investor, BNY Mellon, Research, ESG, GLOBE, Technology, Parity, Intermediary, EGM, State Street, Paper, HSBC, Efficiency, CEO, Industry, Proxymity, Partnership, State, Entrepreneurship, AGM, SRD, Legislation, J. P. Morgan, Deutsche Bank, Solution, Citigroup, Compliance, Communication, Security (finance)

This move extends the existing partnership between the two organisations who have collaborated successfully to provide improved market efficiency and market communication.

Key Points: 
  • This move extends the existing partnership between the two organisations who have collaborated successfully to provide improved market efficiency and market communication.
  • Issuers will benefit greatly from the reduction in paper, and the increased efficiencies and accuracy provided by electronic delivery, as well as having a local agent in the market."
  • Dean Little, CEO and Co-Founder of Proxymity added, "For several years Proxymity and Lumi have partnered to bring positive change to the Investor Communications landscape, and we're delighted to extend our partnership to reach 100% of issuers in Belgium and Luxembourg.
  • The launch highlights the benefits that digital connections are bringing to the whole industry to issuers and investors alike."